Cargando…
SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
Background: Large doses of basal insulin may do little to improve glycemic. Adding pre-prandial insulin increases the number of injections and complicates treatment. Simplifying medication regimen by decreasing injections may improve compliance and lead to improved Hemoglobin A1c (HbA1c). Traditiona...
Autores principales: | Fazeli, Sasan, Rao, Sanjana, Amdur, Richard, Ehrhardt, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553273/ http://dx.doi.org/10.1210/js.2019-SUN-164 |
Ejemplares similares
-
SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020) -
SUN-683 Was Metformin the Culprit for This Lactic Acidosis?
por: Vemparala, Pranathi, et al.
Publicado: (2020) -
SUN-186 Insulin Antibody Associated Severe Insulin Resistance Leading to Uncontrolled Hyperglycemia
por: Amir, Hajira, et al.
Publicado: (2019) -
SUN-693 What Else Should Be Done in Patients with Uncontrolled Type 2 Diabetes and Severe Insulin Allergy?
por: Elshimy, Ghada, et al.
Publicado: (2020) -
Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)